跳转至内容
Merck
CN

SBR00042

Sigma-Aldrich

Omadacycline

≥98% (HPLC)

登录查看公司和协议定价

经验公式(希尔记法):
C29H40N4O7
分子量:
556.65
MDL编号:
UNSPSC代码:
51101500
NACRES:
NA.76

质量水平

检测方案

≥98% (HPLC)

形式

powder

抗生素抗菌谱

Gram-negative bacteria
Gram-positive bacteria

作用机制

protein synthesis | interferes

储存温度

−20°C

InChI

1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34,36-37,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1

InChI key

JEECQCWWSTZDCK-IQZGDKDPSA-N

一般描述

Omadacycline is an aminomethylcycline, a novel semisynthetic tetracycline-class antibiotic drug.(1)(2) It is distinguished from other tetracycline-class drugs like tigecycline and eravacycline at the C9 position with an aminomethyl substitution.(2)

应用

Mode of Action: Interferes with protein synthesis Antibiotic Activity Spectrum: Gram-negative bacteria and Gram-positive bacteria.

生化/生理作用

Omadacycline displays antimicrobial activities against a broad spectrum of organisms including Gram-positive, Gram-negative, anaerobic, and atypical bacteria.(3)(4) It inhibits bacterial protein synthesis by binding on the 30S subunit of the bacterial ribosome.(1)(2) Omadacycline is also effective against tetracycline efflux proteins in in vitro studies and protects against bacterial tetracycline resistance.(4) It has improved efficacy than other tetracycline drugs against acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP).(1)(2)(5) In nonclinical and ex vivo studies, omadacycline displays a low potential for cardiovascular toxicity.(6)

象形图

Health hazard

警示用语:

Warning

危险声明

危险分类

Lact. - Repr. 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rodrigo M Burgos et al.
Infection and drug resistance, 12, 1895-1915 (2019-07-17)
Tetracyclines have come a long way since they became available almost seven decades ago, with numerous enhancements allowing new agents to overcome bacterial mechanisms of resistance. However, these enhancements come with toxicities and pharmacokinetic disadvantages such as the gastrointestinal side-effects
S Ken Tanaka et al.
Antimicrobial agents and chemotherapy, 60(9), 5247-5253 (2016-06-22)
Omadacycline is a first-in-class aminomethylcycline antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative aerobes and anaerobes and atypical bacterial pathogens. A series of nonclinical studies, including mammalian pharmacologic receptor binding studies, human ether-a-go-go-related gene (hERG) channel binding
Monique R Bidell et al.
Pharmacotherapy, 41(11), 915-931 (2021-09-25)
Oral tetracyclines have been used in clinical practice for over 60 years. One of the most common indications for use of oral tetracyclines is for treatment of adult outpatients with skin and soft infections (SSTIs), including acute bacterial skin and skin
S Ken Tanaka et al.
Bioorganic & medicinal chemistry, 24(24), 6409-6419 (2016-07-30)
Omadacycline is novel, aminomethyl tetracycline antibiotic being developed for oral and intravenous (IV) administration for the treatment of community-acquired bacterial infections. Omadacycline is characterized by an aminomethyl substituent at the C9 position of the core 6-member ring. Modifications at this
A B Macone et al.
Antimicrobial agents and chemotherapy, 58(2), 1127-1135 (2013-12-04)
Omadacycline is the first intravenous and oral 9-aminomethylcycline in clinical development for use against multiple infectious diseases including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and urinary tract infections (UTI). The comparative in vitro activity

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门